Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
refractory multiple myeloma,multiple myeloma,bridging therapy,rrmm,ide-cel,triple-class
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要